Immune checkpoint inhibitors (ICIs), such as those targeting programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), have shown remarkable efficacy in malignancies like melanoma and non-small cell lung cancer. Here, CTLA4 is linked to melanoma.